Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial

Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 fem...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2013-04, Vol.21 (2), p.129-136
Main Authors: Madhu, K., Chanda, K., Saji, M. J.
Format: Article
Language:English
Subjects:
Allergology
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Biomedical and Life Sciences
Biomedicine
Curcuma - chemistry
Curcuma longa
Dermatology
Female
Gastroenterology
Glucosamine - therapeutic use
Humans
Immunology
Knee Joint - drug effects
Male
Middle Aged
Osteoarthritis, Knee - complications
Osteoarthritis, Knee - drug therapy
Pain - drug therapy
Pain - etiology
Pain Measurement - drug effects
Pain Measurement - methods
Pharmacology/Toxicology
Plant Extracts - therapeutic use
Research Article
Rheumatology
Severity of Illness Index
Single-Blind Method
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease ( p  
ISSN:0925-4692
1568-5608
DOI:10.1007/s10787-012-0163-3